The FDA has approved Inlexzo (gemcitabine intravesical system) for the treatment of adult patients with BCG-unresponsive, non-muscle invasive bladder cancer with CIS with or without papillary tumors.

The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive ...

Approval was based on data from the Phase IIb SunRISe-1 trial (NCT04640623), in which Inlexzo demonstrated an 82% complete ...

The indication for the chemotherapy-containing system stipulates use in adults with bacillus Calmette-Guerin ...

The FDA has approved Inlexzo for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

The FDA has signed off on Johnson & Johnson’s highly anticipated bladder cancer drug Inlexzo, marking an advance in the ability to care for patients who otherwise face bladder removal and limit | The ...

The FDA approved Johnson & Johnson's Inlexzo, offering a new bladder cancer treatment option with high response rates for ...

The U.S. Food and Drug Administration has approved Inlexzo (gemcitabine intravesical system) for the treatment of patients ...

TAR-200 eliminated tumors in 82% of patients in a phase 2 trial for patients with high-risk non-muscle-invasive bladder ...

Actress Danielle Fishel shared her breast cancer diagnosis this week, revealing on Monday’s episode of her podcast, “Pod Meets World,” that she is being treated for ductal carcinoma in situ. “It is ...